Global Allogeneic Cell Therapy Market Size & Trends Report Segmented by Source (Stem Cells, HSCs, MSCs, Non-stem Cell Therapies), Application (Oncology, Orthopedics, CVDs, Autoimmune Disorders), End User (Hospitals, ASCs) Forecast to 2030
The global allogeneic cell therapy market is set to witness a growth rate of 25% in the next 5 years. Growing demand for off-the-shelf therapies; advancements in cell engineering and genomic technologies; rising prevalence of chronic and rare diseases; and strong pipeline and clinical trials are some of the key factors driving the allogeneic cell therapy market. To learn more about the research report, download a sample report.
Report Overview
Allogeneic cell therapy involves administering cells from a healthy donor to a patient to treat various medical conditions. Unlike autologous therapies, which use patient's own cells, allogeneic treatments utilize donor cells, enabling the creation of off-the-shelf products that can be readily available for multiple patients. This approach is particularly beneficial in treating diseases such as leukemia, lymphoma, and other blood disorders, where the donor's healthy cells can replace the patient's damaged or diseased cells, promoting recovery and restoring normal function.
To learn more about this report, download the PDF brochure
Growing demand for off-the-shelf therapies to propel market demand
The growing demand for off-the-shelf therapies is a significant driver in the allogeneic cell therapy market. Unlike autologous therapies, which require cells to be sourced and processed from each individual patient, allogeneic cell therapies utilize cells from a single donor to treat multiple patients. This approach reduces production time, lowers costs, and simplifies logistics, making treatments more accessible and scalable. Additionally, the rise in chronic diseases and the need for rapid, cost-effective therapeutic solutions are further boosting the adoption of off-the-shelf therapies, positioning allogeneic cell therapies as a promising and efficient option for addressing unmet medical needs.
Advancements in cell engineering and genomic technologies is driving the market growth
Advancements in cell engineering and genomic technologies are propelling the allogeneic cell therapy market by enabling the development of safer, more effective therapies. Cutting-edge techniques like CRISPR and TALEN allow precise genetic modifications, reducing the risk of immune rejection and enhancing cell functionality. These technologies also improve the scalability and consistency of cell production, ensuring high-quality, off-the-shelf therapies. Furthermore, breakthroughs in immune evasion strategies and enhanced cell viability boost therapeutic potential in various diseases. As a result, innovations in cell and genomic engineering are accelerating clinical development and expanding the application scope of allogeneic cell therapies, driving market growth.
To learn more about this report, download the PDF brochure
Competitive Landscape Analysis
The global allogeneic cell therapy market is marked by the presence of established and emerging market players such as Athersys, Inc., Mesoblast Ltd, BioRestorative Therapies, Inc., Poseida Therapeutics, Inc., Vertex Pharmaceuticals Incorporated, Fate Therapeutics, Allogene Therapeutics, Artiva Biotherapeutics, Inc., Atara Biotherapeutics, Inc., and CRISPR Therapeutics; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Report Scope
| Report Metric | Details |
| Base Year Considered | 2024 |
| Historical Data | 2023 – 2024 |
| Forecast Period | 2025 – 2030 |
| Growth Rate | 25% |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Source, Application |
| Regional Scope |
|
| Key Companies Mapped | Athersys, Inc., Mesoblast Ltd, BioRestorative Therapies, Inc., Poseida Therapeutics, Inc., Vertex Pharmaceuticals Incorporated, Fate Therapeutics, Allogene Therapeutics, Artiva Biotherapeutics, Inc., Atara Biotherapeutics, Inc., and CRISPR Therapeutics among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Global Allogeneic Cell Therapy Market Segmentation
This report by Medi-Tech Insights provides the size of the global allogeneic cell therapy market at the regional- and country-level from 2023 to 2030. The report further segments the market based on source, and application.
Market Size & Forecast (2023-2030), By Source, USD Million
- Stem Cell Therapies
- Hematopoietic Stem Cell Therapies (HSCs)
- Mesenchymal Stem Cell Therapies (MSCs)
- Other Stem Cell Therapies
- Non-stem Cell Therapies
- T-Cell Therapies
- Natural Killer (NK) Cell Therapies
- Other Non-stem Cell Therapies
- Others
Market Size & Forecast (2023-2030), By Application, USD Million
- Oncology
- Cardiovascular Diseases
- Neurological Disorders
- Autoimmune Diseases
- Orthopaedic Disorders
- Haematological Disorders
- Others
Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Strategic Questions Addressed
- What is the market size & forecast of the allogeneic cell therapy market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the allogeneic cell therapy market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
- Introduction
- Introduction
- Market Scope
- Market Definition
- Segments Covered
- Regional Segmentation
- Research Timeframe
- Currency Considered
- Study Limitations
- Stakeholders
- List of Abbreviations
- Key Conferences and Events (2025-2026)
- Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
- Bottom-Up Approach
- Top-Down Approach
- Market Forecasting
- Executive Summary
- Allogeneic Cell Therapy Market Snapshot (2025-2030)
- Segment Overview
- Regional Snapshot
- Competitive Insights
- Market Overview
- Market Dynamics
- Drivers
- Growing demand for off-the-shelf therapies
- Advancements in cell engineering and genomic technologies
- Rising prevalence of chronic and rare diseases
- Strong pipeline and clinical trials
- Restraints
- Immunogenicity and rejection risk
- Complex manufacturing processes
- High development costs and limited reimbursement
- Ethical concerns and regulatory hurdles
- Opportunities
- Expansion into new indications
- Emerging markets
- Strategics collaborations and partnerships
- Integration with advanced technologies
- Key Market Trends
- Growing focus on immuno-oncology
- Manufacturing and scalability improvements
- Unmet Market Needs
- Industry Speaks
- Global Allogeneic Cell Therapy Market Size & Forecast (2023-2030), By Source, USD Million
- Introduction
- Stem Cell Therapies
- Hematopoietic Stem Cell Therapies (HSCs)
- Mesenchymal Stem Cell Therapies (MSCs)
- Other Stem Cell Therapies
- Non-stem Cell Therapies
- T-Cell Therapies
- Natural Killer (NK) Cell Therapies
- Other Non-stem Cell Therapies
- Others
- Global Allogeneic Cell Therapy Market Size & Forecast (2023-2030), By Application, USD Million
- Introduction
- Oncology
- Cardiovascular Diseases
- Neurological Disorders
- Autoimmune Diseases
- Orthopaedic Disorders
- Haematological Disorders
- Others
- Global Allogeneic Cell Therapy Market Size & Forecast (2023-2030), By Region, USD Million
- Introduction
- North America Allogeneic Cell Therapy Market Size & Forecast (2023-2030), By Country, USD Million
- US
- Market Size & Forecast, By Source (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Canada
- Market Size & Forecast, By Source (USD Million)
- Market Size & Forecast, By Application (USD Million)
- US
- Europe Allogeneic Cell Therapy Market Size & Forecast (2023-2030), By Country, USD Million
- UK
- Market Size & Forecast, By Source (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Germany
- Market Size & Forecast, By Source (USD Million)
- Market Size & Forecast, By Application (USD Million)
- France
- Market Size & Forecast, By Source (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Italy
- Market Size & Forecast, By Source (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Spain
- Market Size & Forecast, By Source (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Rest of Europe
- Market Size & Forecast, By Source (USD Million)
- Market Size & Forecast, By Application (USD Million)
- UK
- Asia Pacific (APAC) Allogeneic Cell Therapy Market Size & Forecast (2023-2030), By Country, USD Million
- China
- Market Size & Forecast, By Source (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Japan
- Market Size & Forecast, By Source (USD Million)
- Market Size & Forecast, By Application (USD Million)
- India
- Market Size & Forecast, By Source (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Rest of Asia Pacific
- Market Size & Forecast, By Source (USD Million)
- Market Size & Forecast, By Application (USD Million)
- China
- Latin America (LATAM) Allogeneic Cell Therapy Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Source (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Middle East & Africa (MEA) Allogeneic Cell Therapy Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Source (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Competitive Landscape
- Key Players and their Competitive Positioning
- Key Player Comparison
- Segment-wise Player Mapping
- Market Share Analysis (2024)
- Company Categorization Matrix
- Dominants/Leaders
- New Entrants
- Emerging Players
- Innovative Players
- Key Strategies Assessment, By Player (2023-2025)
- New Product Launches
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Geographic Expansion
- Key Players and their Competitive Positioning
- Company Profiles*
(Business Overview, Financial Performance**, Products Offered, Recent Developments)
- Athersys, Inc.
- Mesoblast Ltd
- BioRestorative Therapies, Inc.
- Poseida Therapeutics, Inc.
- Vertex Pharmaceuticals Incorporated
- Fate Therapeutics
- Allogene Therapeutics
- Artiva Biotherapeutics, Inc.
- Atara Biotherapeutics, Inc.
- CRISPR Therapeutics
- Other Prominent Players
Note *Indicative list
**For listed companies
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Stakeholders like Healthcare Providers; Doctors, Oncologists, Haematologists, and Other Medical Professionals
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts
Data Triangulation
Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data
